<DOC>
	<DOCNO>NCT00814294</DOCNO>
	<brief_summary>The primary objective trial compare reduction mean glycated hemoglobin level ( HbA1c ) 2 dos oral HDV-I placebo type 2 diabetic patient background metformin therapy end 18 week treatment . The secondary objective : - To evaluate effect oral HDV-I versus placebo 7-point glucose test , fast plasma glucose ( FPG ) , insulin , homeostasis model assessment insulin resistance ( HOMA-IR ) , homeostasis model assessment β-cell function ( HOMA-β ) , frequency hypoglycemic event , body weight , lipid level ; - To evaluate safety tolerability oral HDV-I .</brief_summary>
	<brief_title>Study Two Doses Oral HDV-Insulin Placebo With Background Metformin Treatment Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study washout/stabilization period 12 week duration 18-week double-blind treatment period . There total 8 visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 18 70 year , inclusive ; Diagnosis type 2 diabetes mellitus ; Fasting plasma glucose &lt; =250 mg/dL ; BMI &lt; =45 kg/m2 ; HbA1c level follow Screening : On stable dose metformin monotherapy HbA1c &gt; =7.5 % &lt; =9.5 % ; On metformin 1 OAD ( exclude TZD , exenatide , insulin ) HbA1c &gt; =6.8 % &lt; =9.0 % ; Naïve antidiabetic therapy stable dose metformin monotherapy &lt; 12 week HbA1c &gt; =8.0 % &lt; =10.5 % ; Understanding study procedure agreement participate study , give write informed consent ; Women may enrol follow criterion ( addition criterion ) meet : They pregnant ( woman childbearing potential must negative serum pregnancy test Visit 1 ) ; They breastfeed ; They plan become pregnant study ; They hysterectomy tubal ligation 6 month prior study , postmenopausal 1 year , practice method birth control throughout study . History type 1 diabetes and/or history ketoacidosis ; History chronic ( &gt; 2 month ) use insulin therapy recent initiation insulin use intend chronic administration ; Use TZD ( pioglitazone rosiglitazone ) exenatide within 3 month prior Screening ; Use prescription counter weight loss agent within 1 month prior Screening ; Use lipidaltering , antihypertensive , chronic use medication stable 1 month prior Screening ; Use medication may alter blood glucose analysis ; Any serious disorder include cardiac , pulmonary , hepatic , uncontrolled endocrine/metabolic , hematologic/oncologic ( within last 5 year ) , neurologic , psychiatric disease would interfere conduct study interpretation data ; Require regular use medication interfere oral absorption and/or metabolism insulin metformin ; History pancreatitis ; History acquire immune deficiency syndrome human immunodeficiency virus ; History drug alcohol abuse within past 2 year ; Hospitalization cause within 14 day prior study ; History allergic toxic response oral HDVI ; Uncontrolled hypertension : systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 95 mmHg ; Triglycerides &gt; 400 mg/dL ; Aspartate aminotransferase alanine aminotransferase &gt; 2.5 time upper limit normal ( ULN ) ; Creatine phosphokinase &gt; 3 time ULN ; Patients weight loss program ongoing weight loss , start intensive exercise program within 4 week start study ; Use investigational drug within 30 day precede first dose study medication ; Employment research center .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Type 2</keyword>
</DOC>